Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 6/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.60 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CDC25B | P30305 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7147276 | 0.86 | MEN1 (0.67) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5928249 | 0.85 | RAB9A (0.73) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7154868 | 0.83 | MEN1 (0.75) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7150730 | 0.82 | MEN1 (0.62) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7152564 | 0.81 | POLB (0.71) | MEN1KMT2AKCNK3KCNK9MAPT | |
| SCHEMBL7150193 | 0.81 | MEN1 (0.60) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15998541 | 0.81 | HDAC1 (0.71) | MEN1KMT2ASIRT2RAB9ANPC1 | |
| SCHEMBL7152146 | 0.80 | KMT2A (0.69) | MEN1KMT2ARAB9ANPC1KCNK3 | |
| SCHEMBL7155125 | 0.80 | KMT2A (0.69) | MEN1KMT2ARAB9ANPC1KCNK3 | |
| SCHEMBL7148111 | 0.80 | MEN1 (0.65) | MEN1KMT2ARAB9ANPC1KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031874-A1 | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis | CONNOR DAVID THOMAS (US) | 2001-10-18 | — | — | US | claimed |
| EP-1042276-A1 | THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY LLC (US) | 2000-10-11 | — | — | EP | claimed |
| WO-1999032433-A1 | THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | claimed |
| US-6528528-B2 | Inhibitors of 15-lipoxygenase, inhibiting chemotaxis of monocytes | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
| US-20010031874-A1 | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis | CONNOR DAVID THOMAS (US) | 2001-10-18 | — | — | US | disclosed |
| US-6268387-B1 | INHIBITORS OF THE ENZYME 15-LIPOXYGENASE AND ARE INHIBITORS OF MONOCYTE CHEMOTAXIS. | WARNER-LAMBERT COMPANY | 2001-07-31 | — | — | US | disclosed |
| EP-1042276-A1 | THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY LLC (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032433-A1 | THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031874-A1 | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis | TPMT, CTH, CBS | MEN1 3193/4885KMT2A 1976/4885SIRT2 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.